Loading...

Vita 34 AG

V3V.DEXETRA
Healthcare
Medical - Care Facilities
4.18
0.00(0.00%)

Vita 34 AG (V3V.DE) Stock Overview

Explore Vita 34 AG’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

F

Score: N/A

Key Financials

Market Cap72.9M
P/E Ratio28.22
EPS (TTM)$-0.69
ROE0.11%

AI Price Forecasts

1 Week$4.02
1 Month$3.61
3 Months$3.85
1 Year Target$3.67

V3V.DE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Vita 34 AG (V3V.DE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of F, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $3.67.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 28.22 and a market capitalization of 72.9M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for V3V.DEStats details for V3V.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for V3V.DEAnalyst Recommendations details for V3V.DE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

VITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.

CEO

Jakub Julian Baran

Employees

783

Headquarters

Deutscher Platz 5a, Leipzig

Founded

2007

Frequently Asked Questions

;